GenIbet contributes to innovative project dedicated to the treatment of myocardial infarction
CARDIOPATCH’s project mission is to contribute to minimising the negative impact of the disease by developing a novel advanced therapy based on Regenerative Medicine and 3D printing.
Formed by 9 different partners from 6 regions of Spain, France and Portugal, the CARDIOPATCH project aims to develop an advanced therapy model to minimize the impact of myocardial infarction, the heart condition with the highest global mortality.
As a member of this network, GenIbet is providing guidance to the partners that are developing the cells and derivatives that will be used for their regenerative properties in the 3D patch. The company will use its expertise in manufacturing biopharmaceuticals to ensure that the cellular products are manufactured and tested in compliance with current regulatory guidelines and good manufacturing practices.
With GenIbet’s input since the early stages of development, the CARDIOPATCH consortium will be more likely to have a straightforward path in applying this therapy to patients in the future.
A promising therapy model
The CARDIOPATCH therapy model is based on two promising fields: cellular regenerative medicine and 3D printing technology. Combined, they have the potential to create a therapeutic solution that benefits patients with chronic myocardial infarction, allowing them to recover from the disease without the need for long-term pharmacological treatments or further hospitalizations.
Besides GenIbet, the network of partners is composed of hospitals, universities, SMEs and other research centers. The CARDIOPATCH project started in September 2020, will end in April 2023 and is funded by the Interreg Sudoe Programme with 1.064.250€ (European Regional Development Fund).
The Cardiopatch project aims to develop an advance therapy model to minimize the impact of myocardial infarction. At GenIbet, we are providing guidance to the partners that are developing the cells and derivatives that will be used for their regenerative properties in the 3D patch. We are using our expertise in manufacturing biopharmaceuticals to ensure these cellular products are manufactured and tested in compliance with current regulatory guidelines and good manufacturing practices. In other words, we want to ensure these products have high quality and are safe. With GenIbet’s input since early stages of development, the Cardiopatch consortium will be more likely to have a straightforward path in applying this therapy to patients in the future.
Find out more information about the project at https://cardiopatch.eu/.